Laurus Labs Ltd management interview: CDMO Growth, Peptides & 30% Margins: Laurus Labs CEO Reveals Growth Plans
NDTV Profit, 2026-11-01. Video: https://www.youtube.com/watch?v=JNPKnL6acwM
- Capex strategy: Laurus is investing ahead of commercial supply because late-phase CDMO partners generally do not want to change manufacturing sites, batch sizes or locations. Capacity is planned 2, 3 years in advance, based on visibility into customers, projects, reactor needs and scale.
- Margin outlook: Management expects gross margins to remain 60% and above and EBITDA margins above 30%; it said H1 performance may very likely be repeated in H2. Chava does not expect EBITDA margins to fall below 30%, and sees gross margins at 63, 65%.
- CDMO visibility: CDMO revenues are expected to be over 50% by FY27. Crop-sciences projects are underway, but meaningful revenues and likely full utilization of that facility are expected in FY29; the company currently has three CDMO partners.
- Peptide expansion: Laurus is building an integrated peptide capability spanning resins, protected amino acids, SPPS or LPPS, purification and isolation. It has peptide revenues and additional projects, and is considering significant capacity expansion based on project and clinical-program visibility.
- Returns outlook: Net debt to EBITDA is about 1, and management expects it to decline; it does not plan to invest more than it is investing this year. Chava expects RoE to reach about 25% in 24, 36 months.